PDCD1 and renal cell carcinoma: Herein, we present a case in which axitinib successfully reversed primary resistance to anti-PD-1 therapy in a patient with renal cell carcinoma (RCC) associated with Xp11.2 translocation/transcription factor E3 gene fusion (Xp11.2/TFE3).